HOX

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Health, Medical Devices, Stem Cells, Genetics, General Health, Pharmaceutical, Biotechnology, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Research, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

Retrieved on: 
Tuesday, February 20, 2024
HOX, Drug discovery, Research, Partnership, Fine chemical

CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.

Key Points: 
  • CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
  • James Murray, Research Director of Vernalis, said, "This partnership is built on Vernalis's strong record for innovation in drug discovery to generate clinical candidates.
  • We look forward to working closely with Hox to successfully achieve the goals of this collaboration".
  • Nicholas Adams, CEO of Hox Therapeutics, said, "We are delighted to be working with Vernalis on this project.

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

Retrieved on: 
Tuesday, February 20, 2024
HOX, Drug discovery, Research, Partnership, Fine chemical

CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.

Key Points: 
  • CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
  • James Murray, Research Director of Vernalis, said, "This partnership is built on Vernalis's strong record for innovation in drug discovery to generate clinical candidates.
  • We look forward to working closely with Hox to successfully achieve the goals of this collaboration".
  • Nicholas Adams, CEO of Hox Therapeutics, said, "We are delighted to be working with Vernalis on this project.

BOMBAY SAPPHIRE® AND THE HOXTON PARTNER WITH ARTISTS INSPIRED BY THEIR LOCAL CITIES FOR SAW THIS MADE THIS INSTALLATION SERIES

Retrieved on: 
Tuesday, September 5, 2023
Piccadilly line, Perrine, Life, Kingsway, Colosseum, Saw-tooth roof, Chartreuse (liqueur), Emotion, Grand Palais, History, High Holborn, HOX, Creativity, Tattoo, Butter, School, Illustrator, Le Palais, City, Dream, Spirit, Atmosphere, Royal Academy of Arts, Crosstown traffic, The Hoxton, Textile, Frederique, News, Character, Glass, Central line, Interior design, Nightclub, Tea, Engraving, Liquor, El Poblenou

LONDON, Sept. 5, 2023 /PRNewswire/ -- BOMBAY SAPPHIRE and The Hoxton will be coming together to bring an exciting addition to their neighbourhoods in Amsterdam, Barcelona, London, Paris, and Rome as part of the gin brand's Saw This Made This campaign. The Hoxton is a series of hotels that prides itself on supporting local communities, whether that be local food, local creatives, or the local streets and scenes that it calls home around the world. BOMBAY SAPPHIRE is a brand that celebrates creativity both inside the cocktail glass and beyond, and now the two have teamed up to unveil a special, locally flavoured art installation series. BOMBAY SAPPHIRE and the Hoxton will be championing new-gen artists in five European locations in the form of five unique pop-up art installations, with the aim of encouraging guests to discover the creative inspiration all around them.

Key Points: 
  • The Hoxton is a series of hotels that prides itself on supporting local communities, whether that be local food, local creatives, or the local streets and scenes that it calls home around the world.
  • BOMBAY SAPPHIRE is continuing its global mission, calling for everyone to be inspired in their local areas, engage their own creativity, and unlock their creative potential.
  • With BOMBAY SAPPHIRE gin's balanced flavour profile and versatility, it is the ideal canvas for cocktail creativity.
  • The world-renowned gin brand has partnered with the head bartenders at The Hoxton bars to create a series of Saw This, Made This limited-edition cocktails, taking inspiration from the local city.

Stowers scientists investigate the evolution of animal developmental mechanisms, show how some of Earth's earliest animals evolved

Retrieved on: 
Tuesday, June 13, 2023
Human, Vertebrate, Sea, Genetics, Stowers Institute for Medical Research, Embryo, Gibson, Research, Gene expression, Bangladesh Technical Education Board, Current Biology, Animal, Factorization of polynomials, Logic, Biology, Medical research, Gene, NIH, Dinosaur, Vaccine, Agriculture, Science, HOX, Earth

This new knowledge paints a vivid picture of how some of the earliest animals on earth progressed from egg to embryo to adult.

Key Points: 
  • This new knowledge paints a vivid picture of how some of the earliest animals on earth progressed from egg to embryo to adult.
  • "Studying the developmental genetics of Nematostella is sort of like taking a time machine into the very distant past," said Gibson.
  • Most contemporary animals, from insects to vertebrates, develop by forming a head-to-tail series of segments that assume distinct identities depending on their position.
  • This is the first time that scientists have evidence of a molecular basis for segment polarization in a pre-bilaterian animal.

Genes that Form Specific Bones In the Womb Heal them Later in Life

Retrieved on: 
Monday, March 20, 2023
Tissue, Leclerc, DNA, Periosteum, PP1, Life, Fetus, Tibia, Connective tissue, Ageing, Patricia, Research, PP2 (kinase inhibitor), Cell, Doctor of Philosophy, National Institutes of Health, Facial muscles, Bangladesh Technical Education Board, HOX, NYU Langone Health, Development, PP2, Osteoblast, MD, Gene, Fracture, CTSI, Mouse, Pp1, PSC, B cell, Orthopedic surgery, Factorization of polynomials, Ceramic, Wine, Phosphorus, Isaac Leucht

NEW YORK, March 20, 2023 /PRNewswire/ -- Genes long known to control the formation of bones before birth also control bone healing later in life, a new study found.   

Key Points: 
  • NEW YORK, March 20, 2023 /PRNewswire/ -- Genes long known to control the formation of bones before birth also control bone healing later in life, a new study found.
  • Such adjustments guide immature stem cells as they multiply and mature in the womb, say the study authors, to become heart muscle, nerves, bones, etc., and in the right places.
  • Bone is among the tissues that keep pools of stem cells on hand into adulthood, ready to mature into needed replacement cells that maintain healthy tissue and heal broken bones.
  • During aging, such stem cells become depleted, the researchers say, resulting in weaker bones that are more likely to fracture and slower to heal.

Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

Retrieved on: 
Tuesday, November 2, 2021
Engineering, Biology, Calendar, Cancer, Disease, PKU, ET, Private Securities Litigation Reform Act, Investor, Lists of diseases, Telephone, SEC, ID, Medicine, Synthetic biology, Conference, Risk, Company, Webcast, Clinical trial, Metabolism, Nasdaq, HOX, Therapy, Intellectual property, Pharmaceutical industry

During the conference call, the Company will review its financial results and provide a corporate update.

Key Points: 
  • During the conference call, the Company will review its financial results and provide a corporate update.
  • The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers.
  • For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company's website.
  • Ch.B., Synlogic's President and Chief Executive Officer, will present at the following banking conference:
    Jefferies London Healthcare Conference, November 18th and 19th.

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Retrieved on: 
Friday, September 10, 2021

Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including:

Key Points: 
  • Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including:
    SYNB8802 was generally well tolerated in healthy volunteers.
  • Enteric hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis.
  • SYNB8802 is currently undergoing Phase 1 studies in healthy volunteers and patients with enteric hyperoxaluria.
  • Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).

Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

Retrieved on: 
Thursday, August 5, 2021
Company, Investor, Clinical trial, Lists of diseases, Webcast, Industry, Telephone, Biology, Metabolism, Intellectual property, ET, Private Securities Litigation Reform Act, Medicine, Engineering, Conference, Therapy, Cancer, SEC, Synthetic biology, Fireside, ID, Nasdaq, HOX, Calendar, Risk, Disease, Pharmaceutical industry, Broadcasting

The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast.

Key Points: 
  • The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast.
  • During the conference call, the Company will review its financial results and provide a corporate update.
  • The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers.
  • For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company's website.